Bachem Aktie
WKN: 914589 / ISIN: CH0012530207
02.07.2025 10:13:18
|
Efficient Large-scale siRNA Manufacturing: Enzymatic Ligation of Short RNA Fragments
Linear synthesis by continuous-flow SPOS is the current state-of-the-art technology to manufacture oligonucleotide APIs. A very promising alternative, especially to manufacture large quantities, is the enzymatic ligation of short oligonucleotide fragments. This approach offers several advantages compared to the conventional strategy like higher yields and reduced purification burdens. Bachem and Codexis will present a case study focusing on a therapeutically relevant siRNA sequence and benchmark different technologies used to manufacture siRNA fragments. We will discuss a wholistic view of the manufacturing process and review control strategies for residual enzyme.The post Efficient Large-scale siRNA Manufacturing: Enzymatic Ligation of Short RNA Fragments appeared first on Bachem.Weiter zum vollständigen Artikel bei Bachem Holding AG

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Bachem AGmehr Nachrichten
Keine Nachrichten verfügbar. |